Related Experiment Videos
188Re DD-3B6/22 Fab' for use in therapy of ovarian cancer: labelling and animal studies
P F Schmidt1, S V Smith, P G Bundesen
1Radiopharmaceutical Division Research and Development, Australian Nuclear Science and Technology Organisation (ANSTO), Menai, NSW.
Abstract:
A fast and high yielding method of 188Re radiolabelling DD-3B6/22 Fab' is described. An inert atmosphere [N2(g)] and ascorbic acid was essential for preparation and storage of therapeutic levels (< or =2 GBq/mg) for up to 24 h. Immunoreactivity was greater than 75%. Pharmacokinetic studies in nu/nu mice demonstrated localisation of 188Re DD-3B6/22 Fab' was equivalent and correlated well with the behaviour observed for 99mTc DD-3B6/22 Fab' used to image ovarian cancer. Excellent stability at the target site in vivo supports the potential use of 188Re DD-3B6/22 Fab' in the therapy of ovarian cancer.